Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
about
Cardiovascular disease and type 1 diabetes: prevalence, prediction and management in an ageing populationRenal endothelial dysfunction in diabetic nephropathyAsymmetric Dimethylarginine and Its Relation As a Biomarker in Nephrologic DiseasesAsymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studiesBiomarkers in chronic kidney disease, from kidney function to kidney damageSymmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuriaType 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.The use of targeted biomarkers for chronic kidney disease.Circulating levels of dimethylarginines, chronic kidney disease and long-term clinical outcome in non-ST-elevation myocardial infarction.The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study.Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2 diabetes: relation with the glycemic control.Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD.Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitusAssociation between Body Mass Index, Asymmetric Dimethylarginine and Risk of Cardiovascular Events and Mortality in Norwegian Patients with Suspected Stable Angina Pectoris.Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective StudiesSmall Molecule Inhibitors of Protein Arginine Methyltransferases.Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.Cellular ADMA: regulation and action.ADMA predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus undergoing coronary angiographyEndogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?Supplementation with Phycocyanobilin, Citrulline, Taurine, and Supranutritional Doses of Folic Acid and Biotin-Potential for Preventing or Slowing the Progression of Diabetic Complications.Perspective in chronic kidney disease: targeting hypoxia-inducible factor (HIF) as potential therapeutic approach.Role of asymmetrical dimethylarginine in the progression of renal disease.Reversibility of endothelial dysfunction in diabetes: role of polyphenols.Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.The L-arginine/NO pathway, homoarginine, and nitrite-dependent renal carbonic anhydrase activity in young people with type 1 diabetes mellitus.Metabolomic Profiling of Arginine Metabolome Links Altered Methylation to Chronic Kidney Disease Accelerated Atherosclerosis.The differences of asymmetric dimethylarginine removal by different dialysis treatments.Role of asymmetric dimethylarginine in cardiovascular disease and diabetes.The alteration of asymmetric dimetilarginine (ADMA) levels in cardiac and gastrocnemius muscles following radioactive iodine application in guinea pigs and the effect of L-carnitine on this alteration.Carotid Plaque Score and Risk of Cardiovascular Mortality in the Oldest Old: Results from the TOOTH Study.Asymmetric dimethylarginine in young people with Type 1 diabetes: a paradoxical association with HbA(1c).Glomerular Endothelial Cells Stress and Cross-Talk With Podocytes in the Development of Diabetic Kidney Disease.A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat.Decrease of asymmetric dimethylarginine predicts acute mountain sickness
P2860
Q26777077-2B8F622D-EAF8-4297-9046-43E285868C06Q27021318-8592F3A6-EA46-45DD-812D-155C2FDB7FDAQ28078222-AFFCB8A3-1CCC-4830-A2B6-55B2C9C03CA7Q28087272-A0F33423-316E-490C-B297-3217F3F8E493Q28087304-E4313FEB-BDD8-41F2-88E5-40A6412E0CCAQ33893655-6BE78C3A-75A2-42CD-990A-404F41DBF151Q34219439-66151606-3504-48CC-A300-7FBE8338628EQ34346928-C560F339-60F5-4230-A006-34FF2A70AD85Q34489684-87AC824E-210E-431A-9C64-B3231DB0F97FQ34632841-E655D1FE-82B3-4593-BFFC-39083C8D8095Q34670457-7C7614EB-025B-4989-8FC4-007505FAB5FDQ35228536-A1465011-54D4-4DE1-B968-F97FDF00200BQ35622245-EAEAC045-1866-4D13-9F89-2E3E509360D8Q35966113-5ACD28B2-57D9-47D3-B43E-7E454712E427Q36182184-E9526D80-C1E6-43F3-8D36-87C25505E595Q37056442-EE7EA914-217F-46AD-9D9A-3A8FCD109FE7Q37211043-2037EFC7-35C5-4EB7-8932-8A740FC0A20FQ37399711-12645354-0BB9-4C89-BEBE-2A2195EC41D3Q37646687-4D2F7001-7BA5-4301-A867-051ECB2C6075Q37684919-7A485CDF-6584-4822-A931-3A9FD1D8E142Q37728038-C9643124-BD08-45F7-9A5A-8E356195DBBDQ37977513-35209382-0179-42AB-A3EF-7FCB405EC8B9Q38046935-E12FBA94-FF60-42BA-BC60-482EDA106206Q38855635-25CDC5AA-84A4-4F6F-A6F2-D5339A7FC5B4Q39631863-409DCDD5-042B-47EC-944C-9729A219CAD1Q40783699-B6A2905B-6A7A-4249-A211-461747C27C85Q41979223-E5E3B475-9A92-4CFA-93A0-35DF5303FA48Q42932776-B7946284-9FAE-4242-A772-E9E0AFCDD1A6Q43061621-56EA4F8A-968D-408D-81E6-A70BCE00A54AQ46221433-C71A4DEE-594B-42E8-9FC0-482DDD435283Q50255281-2BC679E9-A166-4AA4-B34B-BF5DD904A0C1Q51158383-0F39A903-FAF4-44C1-B39A-225B66BAFCF2Q52599406-EA3B55EE-A3BE-4204-BEDE-310EA9CF8398Q53644051-98FD3B12-9DEA-4D18-AA95-B658E6FF9552Q57098141-C7284146-D5B2-468B-B62C-12276547F160
P2860
Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Plasma concentration of asymme ...... nts with diabetic nephropathy.
@en
Plasma concentration of asymmetric dimethylarginine
@nl
type
label
Plasma concentration of asymme ...... nts with diabetic nephropathy.
@en
Plasma concentration of asymmetric dimethylarginine
@nl
prefLabel
Plasma concentration of asymme ...... nts with diabetic nephropathy.
@en
Plasma concentration of asymmetric dimethylarginine
@nl
P2093
P50
P356
P1433
P1476
Plasma concentration of asymme ...... nts with diabetic nephropathy.
@en
P2093
Hans-Henrik Parving
Maria Lajer
Tom Teerlink
P304
P356
10.2337/DC07-1762
P407
P577
2007-12-27T00:00:00Z